Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC cut its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 32.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 323,908 shares of the medical research company's stock after selling 154,930 shares during the period. Geode Capital Management LLC owned about 1.16% of Bio-Rad Laboratories worth $108,124,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC increased its position in shares of Bio-Rad Laboratories by 9.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 947 shares of the medical research company's stock worth $259,000 after acquiring an additional 82 shares during the period. Fifth Third Bancorp raised its position in Bio-Rad Laboratories by 12.2% during the 2nd quarter. Fifth Third Bancorp now owns 12,595 shares of the medical research company's stock valued at $3,440,000 after purchasing an additional 1,368 shares in the last quarter. Capital Advisors Ltd. LLC lifted its holdings in shares of Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock worth $26,000 after buying an additional 62 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Bio-Rad Laboratories by 26.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 196,821 shares of the medical research company's stock worth $53,754,000 after buying an additional 41,461 shares during the period. Finally, State of Michigan Retirement System grew its position in shares of Bio-Rad Laboratories by 3.5% during the 2nd quarter. State of Michigan Retirement System now owns 5,950 shares of the medical research company's stock worth $1,625,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Up 0.6 %

Shares of BIO stock traded up $2.00 during mid-day trading on Thursday, hitting $325.94. 182,453 shares of the stock traded hands, compared to its average volume of 240,908. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $387.99. The stock has a market cap of $9.13 billion, a P/E ratio of -11.93 and a beta of 0.90. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The stock's fifty day moving average is $341.06 and its two-hundred day moving average is $322.09.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company had revenue of $649.70 million during the quarter, compared to analysts' expectations of $628.18 million. During the same quarter in the prior year, the company posted $2.33 earnings per share. Bio-Rad Laboratories's revenue for the quarter was up 2.8% compared to the same quarter last year. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on BIO. Royal Bank of Canada lifted their price objective on Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an "outperform" rating in a report on Monday, December 9th. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target for the company. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Finally, Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories has an average rating of "Moderate Buy" and an average target price of $394.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.